Good response rates and predictors during the first year of cabergoline treatment in large invasive prolactinomas


Bostan H., UÇAN B., Duger H., Hepsen S., Kayihan S., DİLLİ A., ...Daha Fazla

Pituitary, cilt.28, sa.2, 2025 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 28 Sayı: 2
  • Basım Tarihi: 2025
  • Doi Numarası: 10.1007/s11102-025-01512-5
  • Dergi Adı: Pituitary
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
  • Anahtar Kelimeler: Dopamine agonists, Cabergoline, Invasion, Macroprolactinoma, Giant prolactinoma, Hyperprolactinemia
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Purpose: The factors predicting the long-term response to cabergoline are not well known, particularly in more invasive prolactinomas. This study aimed to evaluate the rate of good response (GR) (normoprolactinemia and ≥ 50% tumor shrinkage) at the one-year follow-up and to identify predictors of GR in patients with large invasive prolactinomas. Methods: This retrospective single-center study included 38 patients (32 males, 6 females; mean age 41.9 ± 12.8 years) with invasive macroprolactinomas (baseline median prolactin: 2530 (1726–5451) ng/mL, mean longest tumor diameter: 36.4 ± 12.8 mm) who were followed for at least one year under cabergoline therapy. Prolactin levels and tumor volume changes were analyzed at early and late follow-ups. Patients were classified as good responders (GRs) or poor responders (PRs) based on their first-year outcomes. Results: At the first year, 17 patients (44.7%) achieved a GR. Baseline parameters were comparable between groups, but GRs had significantly higher normoprolactinemia rates (70.6% vs. 23.8%,p = 0.004) and greater tumor shrinkage (57.3 ± 15.6% vs. 41.9 ± 21.9%,p = 0.02) at 3–6 months. An early tumor shrinkage cut-off rate of 44.9% (88% sensitivity, 62% specificity) or an early prolactin cut-off level of 30 ng/mL (75% sensitivity, 77% specificity) were identified as good predictors of GR in the first-year. All GRs maintained normoprolactinemia and ≥ 50% tumor shrinkage, while 33.3% and 42.9% of PRs failed to meet these goals, respectively, at the last visit (p = 0.009, p = 0.002). Three of PRs required surgery during follow-up. Conclusions: Approximately half of invasive prolactinoma patients achieved the composite goal within one year of cabergoline therapy. Early follow-up studies, rather than baseline characteristics, are strong predictors of treatment success.